Abstract
Lower respiratory tract infection (LRTI) is a leading cause of mortality, yet accurate diagnosis remains challenging. We studied two prospective observational cohorts of critically ill patients with acute respiratory failure (pediatric, N=261; adult N=202) and analyzed RNA sequencing data from tracheal aspirate collected following intubation. Patients with LRTI or non-infectious acute respiratory failure were adjudicated by a multi-physician team. We found that FABP4 expression was significantly downregulated in children with confirmed LRTI compared to those with non-infectious respiratory failure, and when incorporated into a diagnostic classifier, achieved an area under the receiver operating characteristic curve (AUC) of 0.90±0.07. When tested in the adult cohort, and AUC of 0.85±0.12 was attained. These findings suggest that pulmonary FABP4 could serve as a valuable biomarker for the early diagnosis of LRTI in critically ill patients across the age spectrum, offering a potential tool for improving clinical outcomes and reducing unnecessary antibiotic use.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
5R01HL155418 (CRL, PMM); Chan Zuckerberg Biohub San Francisco (CRL); R35HL140026 (CSC); R01HL124103 (PMM)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The pediatric cohort study was approved by the Collaborative Pediatric Critical Care Research IRB at the University of Utah (protocol #00088656). Informed consent was obtained from parents or other legal guardians. The adult cohort was approved by the University of California Institutional Review Board (protocol #10-02701) and informed consent was obtained from patients or surrogate decision makers.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: 5R01HL155418 (CRL, PMM); Chan Zuckerberg Biohub San Francisco (CRL); R35HL140026 (CSC); R01HL124103 (PMM)
Data Availability
All data, code, and results are available at: https://github.com/infectiousdisease-langelier-lab/LRTI_FABP4_classifier for reviewing and reproducing the analyses.
https://github.com/infectiousdisease-langelier-lab/LRTI_FABP4_classifier
